

CADTH RAPID RESPONSE REPORT: SUMMARY OF ABSTRACTS

# Prevention of Tuberculosis Reactivation: Clinical Utility and Guidelines

Service Line: Rapid Response Service  
Version: 1.0  
Publication Date: July 14, 2020  
Report Length: 7 Pages

**Authors:** Diksha Kumar, Suzanne McCormack

**Cite As:** *Prevention of Tuberculosis Reactivation: Clinical Utility and Guidelines*. Ottawa: CADTH; 2020 Jul. (CADTH rapid response report: summary of abstracts).

**Disclaimer:** The information in this document is intended to help Canadian health care decision-makers, health care professionals, health systems leaders, and policy-makers make well-informed decisions and thereby improve the quality of health care services. While patients and others may access this document, the document is made available for informational purposes only and no representations or warranties are made with respect to its fitness for any particular purpose. The information in this document should not be used as a substitute for professional medical advice or as a substitute for the application of clinical judgment in respect of the care of a particular patient or other professional judgment in any decision-making process. The Canadian Agency for Drugs and Technologies in Health (CADTH) does not endorse any information, drugs, therapies, treatments, products, processes, or services.

While care has been taken to ensure that the information prepared by CADTH in this document is accurate, complete, and up-to-date as at the applicable date the material was first published by CADTH, CADTH does not make any guarantees to that effect. CADTH does not guarantee and is not responsible for the quality, currency, propriety, accuracy, or reasonableness of any statements, information, or conclusions contained in any third-party materials used in preparing this document. The views and opinions of third parties published in this document do not necessarily state or reflect those of CADTH.

CADTH is not responsible for any errors, omissions, injury, loss, or damage arising from or relating to the use (or misuse) of any information, statements, or conclusions contained in or implied by the contents of this document or any of the source materials.

This document may contain links to third-party websites. CADTH does not have control over the content of such sites. Use of third-party sites is governed by the third-party website owners' own terms and conditions set out for such sites. CADTH does not make any guarantee with respect to any information contained on such third-party sites and CADTH is not responsible for any injury, loss, or damage suffered as a result of using such third-party sites. CADTH has no responsibility for the collection, use, and disclosure of personal information by third-party sites.

Subject to the aforementioned limitations, the views expressed herein do not necessarily reflect the views of Health Canada, Canada's provincial or territorial governments, other CADTH funders, or any third-party supplier of information.

This document is prepared and intended for use in the context of the Canadian health care system. The use of this document outside of Canada is done so at the user's own risk.

This disclaimer and any questions or matters of any nature arising from or relating to the content or use (or misuse) of this document will be governed by and interpreted in accordance with the laws of the Province of Ontario and the laws of Canada applicable therein, and all proceedings shall be subject to the exclusive jurisdiction of the courts of the Province of Ontario, Canada.

The copyright and other intellectual property rights in this document are owned by CADTH and its licensors. These rights are protected by the Canadian *Copyright Act* and other national and international laws and agreements. Users are permitted to make copies of this document for non-commercial purposes only, provided it is not modified when reproduced and appropriate credit is given to CADTH and its licensors.

**About CADTH:** CADTH is an independent, not-for-profit organization responsible for providing Canada's health care decision-makers with objective evidence to help make informed decisions about the optimal use of drugs, medical devices, diagnostics, and procedures in our health care system.

**Funding:** CADTH receives funding from Canada's federal, provincial, and territorial governments, with the exception of Quebec.

Questions or requests for information about this report can be directed to [requests@cadth.ca](mailto:requests@cadth.ca)

## Research Questions

1. What is the clinical utility of screening for latent tuberculosis infection in people at risk of tuberculosis reactivation?
2. What is the clinical utility of treating latent tuberculosis infection to prevent tuberculosis reactivation?
3. What are the evidence-based guidelines for the prevention of tuberculosis reactivation?

## Key Findings

One network meta-analysis and one non-randomized study were identified regarding the clinical utility of treating latent tuberculosis infection to prevent tuberculosis reactivation. Two evidence-based guidelines were identified regarding the prevention of tuberculosis reactivation. No literature was identified regarding the clinical utility of screening for latent tuberculosis infection in people at risk of tuberculosis reactivation.

## Methods

A limited literature search was conducted by an information specialist on key resources including Medline, the Cochrane Library, the University of York Centre for Reviews and Dissemination (CRD) databases, the websites of Canadian and major international health technology agencies, as well as a focused internet search. The search strategy was comprised of both controlled vocabulary, such as the National Library of Medicine’s MeSH (Medical Subject Headings), and keywords. The main search concepts were latent tuberculosis and reactivation. Search filters were applied to limit retrieval to guidelines for Q3 only. Where possible, retrieval was limited to the human population. The search was also limited to English language documents published between January 1, 2015 and June 24, 2020. Internet links were provided, where available.

This report is a component of a larger CADTH Condition Level Review on tuberculosis. A condition level review is an assessment that incorporates all aspects of a condition, from prevention, detection, treatment, and management. For more information on CADTH’s Condition Level Review of tuberculosis, please visit the project page (<https://www.cadth.ca/tuberculosis>).

## Selection Criteria

One reviewer screened citations and selected studies based on the inclusion criteria presented in Table 1.

**Table 1: Selection Criteria**

<b>Populations</b>	Q1: Individuals at risk of LTBI or TB reactivation Q2: Individuals with LTBI Q3: Individuals with LTBI or who are at risk of LTBI or TB reactivation
<b>Interventions</b>	Q1: Screening for LTBI using the tuberculin skin test or interferon-gamma release assay Q2: Treatment for LTBI Q3: Strategies and approaches to prevent TB reactivation
<b>Comparators</b>	Q1: No screening for LTBI Q2: No treatment for LTBI Q3: Not applicable

<b>Outcomes</b>	<p>Q1: Clinical utility (e.g., patients receiving treatment for LTBI, TB reactivation, adverse effects of treatment)</p> <p>Q2: Clinical utility (e.g., TB reactivation, need for subsequent treatment for active TB, adverse effects of LTBI treatment, anxiety)</p> <p>Q3: Recommendations regarding strategies to reduce TB reactivation</p>
<b>Study Designs</b>	Health technology assessments, systematic reviews, randomized controlled trials, non-randomized studies, evidence-based guidelines

LTBI = latent tuberculosis infection; TB = tuberculosis

## Results

One network meta-analysis<sup>1</sup> and one non-randomized study<sup>2</sup> were identified regarding the clinical utility of treating latent tuberculosis infection (LTBI) to prevent tuberculosis (TB) reactivation. Two evidence-based guidelines<sup>3,4</sup> were identified regarding the prevention of TB reactivation. No literature was identified regarding the clinical utility of screening for LTBI in people at risk of TB reactivation. No relevant health technology assessments and randomized controlled trials were identified.

References of potential interest that did not meet the inclusion criteria are provided in the appendix.

## Overall Summary of Findings

One network meta-analysis<sup>1</sup> and one non-randomized study<sup>2</sup> were identified regarding the clinical utility of treating LTBI to prevent TB reactivation. The authors of the network meta-analysis<sup>1</sup> found that compared to no treatment, weekly rifampine-isoniazid regimens were more efficacious in preventing active TB in patients with LTBI. The authors of the non-randomized study<sup>2</sup> found that individuals with LTBI were at a higher risk of developing active TB if they did not undergo treatment.

Two evidence-based guidelines<sup>3,4</sup> were identified regarding the prevention of TB reactivation. A summary of relevant recommendations is presented in Table 2.

No relevant literature was found regarding the clinical utility of screening for LTBI in people at risk of TB reactivation; therefore, no summary can be provided.

**Table 2: Summary of Relevant Recommendations**

Summary of Recommendations	
National Institute for Health and Care Excellence, 2017 <sup>3</sup>	
<ul style="list-style-type: none"> <li>• New entrants from high incidence countries should be screened for LTBI (page 51).</li> <li>• New entrants positive for LTBI should be offered treatment if they are aged 65 years or younger and confirmed to be negative for active TB (page 51).</li> <li>• New entrants positive for LTBI who are not offered treatment should be provided with “inform and advise” information (page 51).</li> </ul>	
United States Preventative Services Task Force, 2016 <sup>4</sup>	
<ul style="list-style-type: none"> <li>• Asymptomatic adults at increased risk of TB infection should be screened for LTBI, including individuals who were born in, or are former residents of high incidence countries and individuals who live in, or have lived in, high-risk settings such as homeless shelters and correctional facilities.</li> </ul>	

LTBI = latent tuberculosis infection; TB = tuberculosis

## References Summarized

### Health Technology Assessments

No literature identified.

### Systematic Reviews and Meta-Analyses

1. Zenner D, Beer N, Harris RJ, Lipman MC, Stagg HR, van der Werf MJ. Treatment of Latent Tuberculosis Infection: An Updated Network Meta-analysis. *Ann Intern Med.* 2017;167(4):248-255. <https://pubmed.ncbi.nlm.nih.gov/28761946/>

### Randomized Controlled Trials

No literature identified.

### Non-Randomized Studies

2. Zenner D, Loutet MG, Harris R, Wilson S, Ormerod LP. Evaluating 17 years of latent tuberculosis infection screening in north-west England: a retrospective cohort study of reactivation. *Eur Respir J.* 2017 07;50(1):07.  
[PubMed: PM28751410](#)

### Guidelines and Recommendations

3. National Institute for Health and Care Excellence. Tuberculosis. (NICE guideline NG33); 2017. <https://www.nice.org.uk/guidance/ng33/resources/tuberculosis-pdf-1837390683589>  
*See: 1.6.2 Opportunistic case finding, page 51*
4. Latent Tuberculosis Infection: Screening. Rockville (MD): U.S. Preventive Services Task Force. 2016.  
<https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/latent-tuberculosis-infection-screening>

## Appendix — Further Information

### Previous CADTH Reports

5. Screening for Latent Tuberculosis Infection in Post-Secondary Institutions: Clinical Utility, Cost-Effectiveness, and Guidelines. (*CADTH Rapid response report: summary of abstracts*). Ottawa (ON): CADTH; 2020. <https://cadth.ca/screening-latent-tuberculosis-infection-post-secondary-institutions-clinical-utility-cost>
6. Latent Tuberculosis Infection Testing in People with Compromised Immunity Prior to Biologic Therapy: Diagnostic Accuracy, Clinical Utility and Guidelines. (*CADTH Rapid response report: summary of abstracts*). Ottawa (ON): CADTH; 2020. <https://cadth.ca/latent-tuberculosis-infection-testing-people-compromised-immunity-prior-biologic-therapy-diagnostic>
7. Occupational Screening for Latent Tuberculosis: Clinical Utility, Cost-Effectiveness, and Guidelines. (*CADTH Rapid response report: summary of abstracts*). Ottawa (ON): CADTH; 2020. <https://cadth.ca/occupational-screening-latent-tuberculosis-clinical-utility-cost-effectiveness-and-guidelines>

### Systematic Reviews and Meta-Analyses – Unknown Comparator

8. Greenaway C, Pareek M, Abou Chakra CN, et al. The effectiveness and cost-effectiveness of screening for latent tuberculosis among migrants in the EU/EEA: a systematic review. *Euro Surveill*. 2018 04;23(14):04. [PubMed: PM29637889](https://pubmed.ncbi.nlm.nih.gov/29637889/)

### Non-Randomized Studies – No Comparator

9. Al-Taweel T, Strohl M, Pai M, et al. A Study of Optimal Screening for Latent Tuberculosis in Patients with Inflammatory Bowel Disease. *Dig Dis Sci*. 2018 10;63(10):2695-2702. [PubMed: PM29968143](https://pubmed.ncbi.nlm.nih.gov/29968143/)
10. Ramos GP, Stroh G, Al-Bawardy B, Faubion WA, Papadakis KA, Escalante P. Outcomes of Treatment for Latent Tuberculosis Infection in Patients With Inflammatory Bowel Disease Receiving Biologic Therapy. *Inflamm Bowel Dis*. 2018 09 15;24(10):2272-2277. [PubMed: PM29718223](https://pubmed.ncbi.nlm.nih.gov/29718223/)

### Review Articles

11. Ai JW, Ruan QL, Liu QH, Zhang WH. Updates on the risk factors for latent tuberculosis reactivation and their managements. *Emerg Microbes Infect*. 2016 Feb 03;5:e10. [PubMed: PM26839146](https://pubmed.ncbi.nlm.nih.gov/26839146/)

### Additional References

12. Canadian Paediatric Society. Approaches to detecting tuberculosis in children and youth. 2018. <https://www.cps.ca/en/documents/position/approaches-to-detecting-tuberculosis-in-children-and-youth>

13. European Centre for Disease Prevention and Control. Review of reviews and guidelines on target groups, diagnosis, treatment and programmatic issues for implementation of latent tuberculosis management. Stockholm (SE): ECDC; 2018 <https://www.ecdc.europa.eu/sites/default/files/documents/October-2018-Review-guidelines-latent-TB-management.pdf>
14. Kiazzyk S, Ball TB. Latent tuberculosis infection: An overview. *Can Commun Dis Rep.* 2017;43(3-4):62-66. <https://pubmed.ncbi.nlm.nih.gov/29770066/>
15. Krause V, National Tuberculosis Advisory C. Policy recommendation: latent tuberculosis infection screening and treatment in children in immigration detention. *Commun Dis Intell Q Rep.* 2015 Dec 31;39(4):E597-598. [PubMed: PM26779733](https://pubmed.ncbi.nlm.nih.gov/26779733/)
16. Public Health England. Tuberculosis (TB): collaborative strategy for England. 2015. [https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment\\_data/file/403231/Collaborative\\_TB\\_Strategy\\_for\\_England\\_2015\\_2020\\_.pdf](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/403231/Collaborative_TB_Strategy_for_England_2015_2020_.pdf)  
See: *A8 Systematically implement new entrant latent TB (LTBI) screening, page 30*